Expanded access to experimental cancer drug
Part of Cancer, Infections, Skin clinical trials.
This program gives access to an experimental drug called IFx-Hu2.0 for people with advanced cancer who have no other treatment options. It aims to see if the drug can help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- This trial is for people with advanced cancer.
- You must be willing to try an experimental treatment.
- Your doctor must agree that you have no other good options.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medicines—an oral therapy (ASTX727) and an immunotherapy (retifanlimab)—for people with advanced Merkel cell carcinoma that has not responded to prior immunotherapy. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
This trial studies OH2 injection given directly into a melanoma tumor, combined with HX008, to see if it can shrink tumors after standard treatments—including PD-1—did not work. It may help people with advanced melanoma, especially when there is a reachable tumor for injection.
This study tests a new drug called PF-08046033 in people with advanced lung cancer (NSCLC), esophageal cancer (ESCC), or melanoma (skin cancer) that has spread or can't be surgically removed. The drug targets a specific protein to help slow or stop cancer growth.
This trial tests a new drug called MDX2004 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if the drug is safe and if it helps shrink tumors.
Hear when a new Cutaneous Melanoma, Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.